RxSight (NASDAQ:RXST – Get Free Report) was upgraded by research analysts at UBS Group to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports. Weiss Ratings lowered shares of RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Jefferies Financial Group set a $6.50 target price on shares of RxSight in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded shares of RxSight from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the stock.